Cystatin C tied to worse heart failure outcomes across ejection fraction spectrum

Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with heart failure (HF) across the ejection fraction (EF) spectrum, according to a study published in Clinical Cardiology.